Beyond Air Exits NeuroNOS Stake for UNIVO Equity and $32.5M Milestones
Event summary
- Beyond Air sells its 58% stake in NeuroNOS to UNIVO for 19.99% UNIVO equity and warrants.
- Deal includes up to $32.5M in milestone payments tied to NeuroNOS drug development.
- NeuroNOS focuses on treatments for autism, glioblastoma, and Alzheimer’s.
- Transaction expected to close pending regulatory and shareholder approvals.
- Beyond Air retains IP rights and receives milestone payments for transferred assets.
The big picture
Beyond Air’s exit from NeuroNOS reflects a strategic realignment toward its core respiratory business, while UNIVO gains control of a promising neurology pipeline. The deal underscores the growing trend of biotech partnerships aimed at accelerating drug development, particularly in complex neurological disorders. With up to $32.5M in milestone payments at stake, Beyond Air’s financial upside remains tied to NeuroNOS’s success under UNIVO’s leadership.
What we're watching
- Strategic Focus
- Whether Beyond Air can successfully pivot back to its core LungFit business after divesting NeuroNOS.
- Milestone Timing
- The pace at which NeuroNOS achieves development and commercial milestones to unlock Beyond Air’s payments.
- Regulatory Pathway
- How NeuroNOS navigates FDA and other regulatory hurdles for its pipeline candidates.